TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06478017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Patients will receive 10mg/kg on Day 3 post-transplant (72 hours +/- 12 hours post-transplant)~Day 7 post-transplant (+/- 6 hours)~Day 16 (End of Week 2 after 1st dose of belatacept) post-transplant (+/- 2 days)~Day 30 (End of Week 4 after 1st dose of belatacept) post-transplant (+/- 3 days)~Day 58 (Week 8) post-transplant (+/- 3 days)~Day 86 (Week 12) post-transplant (+/- 3 days)~Patients will receive 5mg/kg Every 28 days (+/- 3 days) thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Prograf (tacrolimus) or tacrolimus generic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Prograf (tacrolimus) or tacrolimus generic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil/Sodium
Description: CellCept (mycophenolate mofetil- MMF), or Myfortic (mycophenolate sodium)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil/Sodium
Description: CellCept (mycophenolate mofetil- MMF), or Myfortic (mycophenolate sodium)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Prednisone
Study: NCT06669143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160 mg bid, po, day 1-21, a maximum of 2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg qd, po, day 1-10, a maximum of 2 years.
Study: NCT05628324

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: practice muscle activation patterns
Description: practice upper limb muscle activation patterns using EMG-controlled games

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: task practice
Description: practice functional upper limb tasks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: task practice
Description: practice functional upper limb tasks
Study: NCT06688942

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Horizons App Intervention
Description: Participants will receive access to the Horizons app intervention. The intervention pairs patient-centered information about chronic graft-versus-host disease with self-management strategies. Within each module, patients will engage in didactics and exercises that are relevant to the participant's chronic graft-versus-host disease concerns. The app contains 6 digital modules delivered via tablet over approximately 6 weeks. Each module should take up to approximately 20 minutes and are self-guided.
Study: NCT06617897

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL511 Fibrinogen concentrate (human)
Description: CSL511 will be prepared in sterile water for injection and administered as an intravenous (IV) infusion.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprecipitate
Description: Cryoprecipitate will be administered via IV infusion.
Study: NCT05155605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Cancer Early Detection Test
Description: Blood collection and multi-cancer early detection testing with return of results.
Study: NCT06628921

Intervention type: DRUG
Intervention: Eptinezumab 100 or 300 mg ev
Description: Eptinezumab administered for migraine prevention in patients but with ongoing migraine attacks.

Intervention type: DRUG
Intervention: Eptinezumab 100 or 300 mg ev
Description: Eptinezumab administered for migraine prevention in patients but with ongoing migraine attacks.
Study: NCT05292027

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-dose radiotherapy
Description: On the first and second days of induction chemotherapy, lymph nodes were irradiated with 0.5Gy bid for 4 times.
Study: NCT06712615

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG-102
Description: PG-102 (MG12) is a long-acting dual agonist composed of Double GLP-1E-NTIG and Stable GLP-2 NTIG that targets both GLP-1 and GLP-2 receptors.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG-102
Description: PG-102 (MG12) is a long-acting dual agonist composed of Double GLP-1E-NTIG and Stable GLP-2 NTIG that targets both GLP-1 and GLP-2 receptors.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG-102
Description: PG-102 (MG12) is a long-acting dual agonist composed of Double GLP-1E-NTIG and Stable GLP-2 NTIG that targets both GLP-1 and GLP-2 receptors.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG-102
Description: PG-102 (MG12) is a long-acting dual agonist composed of Double GLP-1E-NTIG and Stable GLP-2 NTIG that targets both GLP-1 and GLP-2 receptors.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG-102
Description: PG-102 (MG12) is a long-acting dual agonist composed of Double GLP-1E-NTIG and Stable GLP-2 NTIG that targets both GLP-1 and GLP-2 receptors.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG-102
Description: PG-102 (MG12) is a long-acting dual agonist composed of Double GLP-1E-NTIG and Stable GLP-2 NTIG that targets both GLP-1 and GLP-2 receptors.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle-based formulation for PG-102

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle-based formulation for PG-102

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle-based formulation for PG-102

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle-based formulation for PG-102

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle-based formulation for PG-102

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle-based formulation for PG-102
Study: NCT06703216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra (Kineret®)
Description: Pre-emptive Anakinra at the initial onset of CRS.
Study: NCT06732180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT-02287
Description: Dose of 13.5 mg/kg/day (plus/minus 2 mg/kg/day based on body weight) to be administered orally once a day for 90 days. Dosage form: powder in sachet (200 mg of GT-02287 per sachet) for reconstitution with a suspending agent
Study: NCT06734832

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent enterovirus vaccine (Vero cell), inactivated
Description: Two doses are administered with a one-month interval between each dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Enterovirus Type 71 Vaccine (Vero Cell), Inactivated
Description: Two doses are administered with a one-month interval between each dose.
Study: NCT06742307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faricimab Injection [Vabysmo]
Description: A planned quarterly (every 12-16 weeks) aflibercept injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab. This intervention schedule is not specifically studied in other literature, although similar schedule exist.
Study: NCT06750523

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cord blood sampling
Description: A cord blood sample will be taken at birth for analysis of oxidative stress markers, endocrine disruptors, and microRNAs.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: urine sampling
Description: At one month of age, urine samples will be collected from newborns to analyze oxidative stress markers and endocrine disruptors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life style questionnaire
Description: At the time of enrollment, mothers will complete a specialized questionnaire designed to assess potential exposure to endocrine disruptors (EDCs) through diet, clothing, and the use of cosmetics and detergents.
Study: NCT06746740

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Adapted with input from phase 1
Study: NCT06702657

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balloon dilatation and/or stenting
Description: balloon dilatation and/or stenting immediately after randomization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medication
Description: medication after randomisation, mechanical thrombectomy again if necessary, avoiding balloon dilatation and/or stenting.
Study: NCT06750978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-reflection
Description: Participants will be guided to identify goals of daily PSU reduction. o Participants will be guided to actively review their smartphone usage data each day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-reflection + Alternative activity engagement
Description: Participants will be guided to identify goals of daily PSU reduction and actively review their smartphone usage data each day. Participants will be guided to develop a plan for alternative activity engagement and confirm their engagement in the alternative activities as planned.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-reflection + Contingency management
Description: Participants will be guided to identify goals of daily PSU reduction and actively review their smartphone usage data each day. Participants will receive an incentive ($8) if they meet the daily PSU reduction goal.
Study: NCT06750913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comparison between PCNL without Catheterization in the Split-leg Prone Position and Traditional PCNL
Description: Before the start of PCNL, one group of patients was placed in the lithotomy position and then converted to the prone position, and one group of patients directly separated from the leg prone position without an external brace
Study: NCT06755359

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: Radioactive sources named Alpha DaRT sources: Ra - 224 coated onto stainless steel tubes inserted into the tumor.
Study: NCT06752265

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peran sadar application
Description: The PERAN SADAR application is an android-based SACA prevention application containing material related to SACA prevention which is given in a series for nine days using multimedia video stories and songs, documents, and tiktok in an attractive package, so that it attracts someone's interest in listening to the contents of the message. Social media applications are educational methods that are popular with all ages
Study: NCT06751797

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05340556

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample of 12 ml EDTA plasma.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Swap test
Description: receive swab tests for collecting cells from the oral mucosa
Study: NCT06168955

Intervention type: OTHER
Group type: OTHER
Intervention: skin biopsy
Description: skin biopsy for cell culture and N-homocysteinylation study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: skin biopsy
Description: skin biopsy for cell culture and N-homocysteinylation study
Study: NCT04948190

Intervention type: BEHAVIORAL
Intervention: Testing with medical detection dogs
Description: Participants will be screened by medical detection dogs. In phase 2, participants may be asked to wear clothing samples collected in phase 1, as part of dog training procedures. In subsequent study parts, participants will wear their own clothing.

Intervention type: BEHAVIORAL
Intervention: Testing with medical detection dogs
Description: Participants will be screened by medical detection dogs. In phase 2, participants may be asked to wear clothing samples collected in phase 1, as part of dog training procedures. In subsequent study parts, participants will wear their own clothing.
Study: NCT05776966

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gender-specific digital intervention (GSDI)
Description: The GSDI is a digital intervention that incorporates factors that are more prevalent in women with opioid use disorder that may affect their treatment outcomes. The content for the intervention was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Participants will receive treatment as usual for opioid use disorder which is a mix of medication treatment and individual and group therapy services across various levels of care.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Participants will receive treatment as usual for opioid use disorder which is a mix of medication treatment and individual and group therapy services across various levels of care.
Study: NCT06752577

Intervention type: DRUG
Intervention: Allogeneic, vertebral bone marrow-derived mesenchymal stem cells (MSC)
Description: Single intravenous infusion of 200x10\^6 cells delivered systemically through a peripheral IV (over 15 minutes to 2 hours)
Study: NCT06753981

Intervention type: DRUG
Intervention: Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs
Description: Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs Including macitentan sildenafil/tadalafil or riociguat selexipag/epoprostenol.
Study: NCT06753721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin liposome combined with CapOX and Bevacizumab
Description: Bevacizumab (7.5 mg/kg, IV, Day 1) + Oxaliplatin (130 mg/m², IV, Day 1) + Capecitabine (1000 mg/m², oral, twice daily, for 14 days) + Doxorubicin liposome (20 mg/m², IV, Day 1), repeated every 3 weeks.
Study: NCT06753643

Intervention type: OTHER
Intervention: The IMPACTFrail programme
Description: The IMPACTFrail programme
Study: NCT06751992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion to extended-release tacrolimus
Description: Conversion from immediate-release tacrolimus (Prograf) to extended-release tacrolimus (Envarsus XR) as a part of the maintenance immunosuppressive treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance of immediate-release tacrolimus
Description: Continuing immediate-release tacrolimus (Prograf) as a part of the maintenance immunosuppressive treatment
Study: NCT06756269

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dose for 15-HPV vaccine
Description: Participants aged 9-45 years were given 3 doses of medium dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose for 15-HPV vaccine
Description: Participants aged 9-45 years were given 3 doses of high dose 15-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants aged 9-45 years were given 3 doses of placebo intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 9-HPV vaccine
Description: Participants aged 9-45 years were given 3 doses of 9-HPV vaccine intramuscular into the upper arm deltoid muscle according to 0, 2, and 6 months immunization schedule
Study: NCT06752967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein liquid test meal
Description: High protein liquid test meal consisting of whey protein, water and sugar-free coadial mix for flavour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High carbohydrate liquid test meal
Description: High carbohydrate liquid test meal consisting of sucrose, water and sugar-free coadial mix for flavour.
Study: NCT04260776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 1: Web-based intervention (MyWebQuit) with 1-way text messages
Description: Participants will receive MyWebQuit (web-based smoking intervention) along with a corresponding 1-way text messages

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phase 1: Web-based intervention (MyWebQuit) with interactive, 2-way text messages
Description: Participants will receive MyWebQuit (web-based smoking intervention) along with corresponding interactive, 2-way text messages
Study: NCT06752863

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypotensive anesthesia in ear, nose and throat surgeries using labetalol and dexmedetomidine infusions
Description: The study compares the role of Labetalol infusion versus Dexmedetomidine infusion in hypotensive anesthesia in patients having ear, nose and throat surgeries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypotensive anesthesia in ear, nose and throat surgeries using labetalol and dexmedetomidine infusions
Description: The study compares the role of Labetalol infusion versus Dexmedetomidine infusion in hypotensive anesthesia in patients having ear, nose and throat surgeries
Study: NCT06752616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sublingual Dexmedetomidine
Description: Sublingual dexmedetomidine 180 mcg, possible second dose 90 mcg after 2 hrs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal midazolam
Description: Buccal midazolam 10 mg, possible second dose 10 mg after 2 hrs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral lorazepam
Description: Oral lorazepam 4 mg, possible second dose 4 mg after 2 hrs
Study: NCT06753474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus influenza A H3N2 strain
Description: Live Influenza Virus RG-A/Texas/71/2017 (H3N2). It is a cell-grown, reverse genetics-derived influenza A virus manufactured to conduct clinical trials that involve controlled human infection with influenza A virus. This influenza human challenge virus was produced for the National Institute of Allergy and Infectious Diseases (NIAID).~The final Drug Product Live Influenza Virus RG-A/Texas/71/2017 (H3N2) (Lot #1507-232149) vial contains 1.86 X 106 median tissue culture infectious doses (TCID50)/mL formulated in 1X sucrose-phosphate-glutamate (SPG; 7.4% sucrose, 3.8 mM KH2PO4, 7.2 mM K2HPO4, 5.4 mM L-glutamic acid) in Ex-Cellä 293 serum-free medium (Sigma-Aldrich). It is susceptible to the FDA-approved neuraminidase (NA) inhibitors (NAI) oseltamivir phosphate, zanamivir, and peramivir, and the polymerase acidic (PA) inhibitor (PAI) baloxavir marboxil.x
Study: NCT06755515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rulonilimab
Description: Drug: Rulonilimab Description: iv, 200mg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Bevacizumab Description: iv, 15mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Cisplatin Description: iv, 50mg/m\^2 every 3 weeks, for up to 6 cycles. Drug: Carboplatin Description: iv, AUC 4\~6 every 3 weeks, for up to 6 cycles. Drug: Paclitaxel Description: iv, 175mg/m\^2 every 3 weeks, for up to 6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: placebo Description: iv, every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Bevacizumab Description: iv, 15mg/kg every 3 weeks, for up to 2 years until disease progression, intolerable toxic reactions, or termination of treatment for other reasons.~Drug: Cisplatin Description: iv, 50mg/m\^2 every 3 weeks, for up to 6 cycles. Drug: Carboplatin Description: iv, AUC 4\~6 every 3 weeks, for up to 6 cycles. Drug: Paclitaxel Description: iv, 175mg/m\^2 every 3 weeks, for up to 6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin/carboplatin + paclitaxel ± bevacizumab
Description: cisplatin/carboplatin + paclitaxel ± bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin/carboplatin + paclitaxel ± bevacizumab
Description: cisplatin/carboplatin + paclitaxel ± bevacizumab
Study: NCT06752356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune globulin (human) 10% solution for intravenous administration
Description: Kedrion intravenous immunoglobulin (IVIg) 10%

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune globulin (human) 10% solution for intravenous administration
Description: Kedrion intravenous immunoglobulin (IVIg) 10%
Study: NCT06751485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JSKN003
Description: Experimental drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Active Comparator
Study: NCT06752252

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided paravertebral block
Description: after sterilization and identifying the level of T10 ,linear ultrasound probe will be placed in the midline over the spinous process at the chosen level, then the probe will be moved laterally to view the lamina and hyperechoic transverse process ,the pleural should be visible as a bright white line .The needle should be inserted in -plane from lateral to medial and the needle tip should end in a hypoechoic triangular space. Correct needle placement should be confirmed by anterior displacement of pleura with injection of small volume of saline then 0.5 ml/kg of a mixture of 0.25 ℅ bupivacaine and 1℅ lidocaine (1:1) will be injected

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided erector spinae plane block
Description: After sterilization, the linear ultrasound probe will be placed over transverse process of T10 ,after optimizing the image in sagittal or transverse scanning ,A 50 mm 22-G needle will be placed under the erector spinae muscle in -in plane orientation until it contacted T8 transverse process in the cranial caudal direction ,after hydro dissection and confirmation that the tip of the needle is between the transverse process and the fascia of the erector spinae muscle group, 0.5 ml/kg of a mixture of 0.25 ℅bupivacaine and 1℅ lidocaine (1:1) will be injected

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: control group C
Description: will receive standard general anesthesia with pain management protocol without regional block.
Study: NCT06754501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given by vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Given by vein